PROM1 and central nervous system cancer: Furthermore, glycosylation of CD133 has been suggested as a secondary CSC indicator [113] In certain glioma CSCs, sialylation of CD133 N-glycan terminal via the α2,3-site is augmented in hypoxic conditions, correlating with brain CSC migration and survival [140,142].